SCHEMBL4438683

SCHEMBL4438683

O=C(O)Cc1ccccc1Sc1ccccc1CC(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.69
HPGD P15428 1/20 0.69
CYP2C19 P33261 1/20 0.69
AKR1B1 P15121 2/20 0.59
MMP2 P08253 1/20 0.58
MMP9 P14780 1/20 0.58
MMP12 P39900 1/20 0.58
TDP1 Q9NUW8 1/20 0.57
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CXCL8 P10145 5/20 0.46
PTGS2 P35354 2/20 0.46
AKR1B10 O60218 1/20 0.46
UGT1A9 O60656 1/20 0.46
TRPA1 O75762 1/20 0.46
ABCB11 O95342 1/20 0.46
MT-CO2 P00403 1/20 0.46
TTR P02766 1/20 0.46
ALB P02768 1/20 0.46
UGT1A6 P19224 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3765157 0.90 HPGD (0.78) CYP2C9HPGDCYP2C19AKR1B1MMP2
SCHEMBL4441106 0.89 CYP2C9 (0.58) CYP2C9HPGDCYP2C19AKR1B1MMP2
SCHEMBL10937060 0.89 CYP2C9 (0.67) CYP2C9HPGDCYP2C19AKR1B1MMP2
SCHEMBL5658529 0.88 TDP1 (0.69) CYP2C9HPGDCYP2C19AKR1B1MMP2
SCHEMBL4828911 0.87 AKR1B1 (0.59) CYP2C9HPGDCYP2C19AKR1B1MMP2
SCHEMBL4438686 0.86 HPGD (0.55) CYP2C9HPGDCYP2C19AKR1B1MMP2
SCHEMBL6792300 0.85 MMP2 (0.60) CYP2C9HPGDCYP2C19AKR1B1MMP2
SCHEMBL8228112 0.84 MMP2 (0.76) CYP2C9HPGDCYP2C19AKR1B1MMP2
SCHEMBL6933325 0.84 CYP2C9 (0.74) CYP2C9HPGDCYP2C19AKR1B1MMP2
SCHEMBL10938090 0.83 PDE7A (0.54) CYP2C9HPGDCYP2C19AKR1B1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8933195-B2 Histone deacetylase inhibitors and synthetic method thereof and use thereof in manufacture of medicaments NANJING YOKO BIOMEDICAL R & D LTD. (CN) 2015-01-13 US disclosed
US-20140243501-A1 HISTONE DEACETYLASE INHIBITORS AND SYNTHETIC METHOD THEREOF AND USE THEREOF IN MANUFACTURE OF MEDICAMENTS NANJING YOKO BIOMEDICAL R & D LTD. [CN/CN] (CN) 2014-08-28 US disclosed
CN-101622227-A Biaryl and biheteroaryl compounds useful in treating iron disorders XENON PHARMACEUTICALS INC 2010-01-06 CN disclosed
EP-2061754-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2009-05-27 EP disclosed
WO-2008115999-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 WO disclosed
US-20080234384-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234384-A1 BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS FECH, SLC10A1, SLC40A1 CYP2C9 228/4885HPGD 575/4885CYP2C19 282/4885
US-20140243501-A1 HISTONE DEACETYLASE INHIBITORS AND SYNTHETIC METHOD THEREOF AND USE THEREOF IN MANUFACTURE OF MEDICAMENTS HDAC1, HDAC11, HDAC2 CYP2C9 3186/4885HPGD 1152/4885CYP2C19 3358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.